Christian U. Blank

2003–2025 年に発表

別表記
Christian U Blank
237
論文数
59,062
被引用数
97
h 指数
228
i10 指数

被引用数

Christian U. Blank の年別被引用数1971 年: 被引用 3 件1995 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 1 件2003 年: 被引用 2 件2004 年: 被引用 5 件2005 年: 被引用 12 件2006 年: 被引用 33 件2007 年: 被引用 62 件2008 年: 被引用 69 件2009 年: 被引用 55 件2010 年: 被引用 67 件2011 年: 被引用 50 件2012 年: 被引用 94 件2013 年: 被引用 193 件2014 年: 被引用 230 件2015 年: 被引用 401 件2016 年: 被引用 737 件2017 年: 被引用 914 件2018 年: 被引用 900 件2019 年: 被引用 2,383 件2020 年: 被引用 3,379 件2021 年: 被引用 3,779 件2022 年: 被引用 3,305 件2023 年: 被引用 2,800 件2024 年: 被引用 4,120 件2025 年: 被引用 2,293 件2026 年: 被引用 47 件1972〜1994 年は被引用が無いため表示していません1996〜1997 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 7,552 件、この内訳の 24.3%中国: 引用元論文 5,048 件、この内訳の 16.2%ドイツ: 引用元論文 1,742 件、この内訳の 5.6%イタリア: 引用元論文 1,558 件、この内訳の 5%イギリス: 引用元論文 1,540 件、この内訳の 5%フランス: 引用元論文 1,415 件、この内訳の 4.6%オランダ: 引用元論文 1,180 件、この内訳の 3.8%オーストラリア: 引用元論文 1,144 件、この内訳の 3.7%スイス: 引用元論文 832 件、この内訳の 2.7%カナダ: 引用元論文 820 件、この内訳の 2.6%スペイン: 引用元論文 818 件、この内訳の 2.6%日本: 引用元論文 796 件、この内訳の 2.6%
0%24.3%その他 21.3%

分野

  • Medicine58.5%
  • Biochemistry, Genetics and Molecular Biology24.2%
  • Immunology and Microbiology13.4%
  • Engineering1.5%
  • Neuroscience0.5%
  • Computer Science0.4%
  • その他1.5%

トピック

  • Cancer Immunotherapy and Biomarkers16%
  • Immunotherapy and Immune Responses7.5%
  • CAR-T cell therapy research5.7%
  • Immune Cell Function and Interaction4.7%
  • Melanoma and MAPK Pathways3.7%
  • Immune cells in cancer3.2%
  • その他59.2%

共著者

全論文

検索で開く
  1. The human tumor microbiome is composed of tumor type–specific intracellular bacteria

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elisa A. Rozeman, Christian U. Blank, Anat Ronai, Ron Shaoul, Amnon Amit, Tatiana Dorfman, Ran Kremer, Zvi R. Cohen, Sagi Harnof, Tali Siegal, Einav Yehuda‐Shnaidman, Einav Nili Gal‐Yam, Hagit Shapira, Nicola Baldini, Morgan G. I. Langille, Alon Ben‐Nun, Bella Kaufman, Aviram Nissan, Talia Golan, Maya Dadiani, Keren Levanon, Jair Bar, Shlomit Yust‐Katz, Iris Barshack, Daniel S. Peeper, Dan J. Raz, Eran Segal, Jennifer A. Wargo, Judith Sandbank, Noam Shental, Ravid Straussman - Science 2020 被引用: 2,471

  2. B cells and tertiary lymphoid structures promote immunotherapy response

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine N. Spencer, Elizabeth M. Burton, Lauren E. Haydu, Alexander J. Lazar, Roberta Zapassodi, Courtney W. Hudgens, Deborah A. Ledesma, SuFey Ong, Michael Bailey, Sarah Warren, Disha Rao, Oscar Krijgsman, Elisa A. Rozeman, Daniel S. Peeper, Christian U. Blank, Ton N. Schumacher, Lisa H. Butterfield, Monika A. Zelazowska, Kevin M. McBride, Raghu Kalluri, James P. Allison, Florent Petitprez, Wolf H. Fridman, Catherine Sautès‐Fridman, Nir Hacohen, Katayoun Rezvani, Padmanee Sharma, Michael T. Tetzlaff, Linghua Wang, Jennifer A. Wargo - Nature 2020 被引用: 2,745

  3. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephan Schreml, Sebastian Haferkamp, Elisabeth Kohl, Sigrid Karrer, Mark Berneburg, Wolfgang Herr, Wolfgang Mueller‐Klieser, Kathrin Renner, Marina Kreutz - Cell Metabolism 2016 被引用: 1,902

  4. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 5,847

  5. Defining ‘T cell exhaustion’

    著者: , , , , , , , , , , , , , , , , , - Nature reviews. Immunology 2019 被引用: 1,584

  6. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , - Science 2015 被引用: 2,995

  7. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A. M. Stevense‐den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan‐Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers‐Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebæk, Lisbet Rosenkrantz Hölmich, Alexander C. J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, A. Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen - New England Journal of Medicine 2022 被引用: 536

  8. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

    著者: , , , , , , , , , , , , , , , , , - Cell 2018 被引用: 1,165

  9. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Levi A. Garraway, Aviv Regev, Keith T. Flaherty, Annette Paschen, Eliezer M. Van Allen, Dirk Schadendorf - Nature Medicine 2019 被引用: 1,105

  10. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,853

  11. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sabine C. Linn, Ton N. Schumacher, Christian U. Blank, Marleen Kok - Nature Medicine 2019 被引用: 889

  12. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 1,153

  13. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rony Kapoor, Aafke Meerveld-Eggink, Lindsay G Grijpink-Ongering, Alexander C. J. van Akkooi, Irene L M Reijers, David E Gyorki, Dirk J Grünhagen, Frank M. Speetjens, Sonja B Vliek, Joanna Placzke, Lavinia Spain, Robert C Stassen, Mona Amini-Adle, Céleste Lebbé, Mark B. Faries, Caroline Robert, Paolo A. Ascierto, Rozemarijn van Rijn, Franchette W P J van den Berkmortel, Djura Piersma, Andre van der Westhuizen, Gerard Vreugdenhil, Maureen J Aarts, Marion A. M. Stevense‐den Boer, Victoria Atkinson, Muhammad Khattak, Miles C Andrews, Alfons J M van den Eertwegh, Marye J Boers-Sonderen, Geke A P Hospers, Matteo S Carlino, Jan-Willem B de Groot, Ellen Kapiteijn, Karijn P M Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid A M van der Veldt, Georgina V Long - New England Journal of Medicine 2024 被引用: 467

  14. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 被引用: 855

  15. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

    著者: , , , , , , , , , , , , , , , - Nature Medicine 2021 被引用: 369

  16. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian U. Blank, Jan Paul de Boer, John B.A.G. Haanen, Charlotte L. Zuur - Nature Communications 2021 被引用: 336

  17. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet 2012 被引用: 2,960

  18. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 230

  19. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2020 被引用: 397

  20. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

    著者: , , , , , , , , , , , , , , , , , , - Nature 2017 被引用: 714

  21. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John B.A.G. Haanen, Robert V. Rawson, Bart A. van de Wiel, Lonneke V. van de Poll‐Franse, Richard A. Scolyer, Annelies H. Boekhout, Georgina V. Long, Christian U. Blank - Nature Medicine 2022 被引用: 357

  22. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

    著者: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2021 被引用: 430

  23. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 1,239

  24. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

    著者: , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 558